Status:
UNKNOWN
Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients
Lead Sponsor:
Institute for Research and Development of Medicinal and Food Plants of Guinea
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Our previous work on plants has indicated significant antimalarial and antiviral activities. Of these plants, two recipes are proposed for evaluation for COVID-19. It is Cinchona, an antimalarial and ...
Detailed Description
All consenting subjects who meet the inclusion criteria will benefit from an individual file which will include data relating to general information, the complete clinical examination and the paraclin...
Eligibility Criteria
Inclusion
- Eligible patients are adults with COVID-19 confirmed by a positive PCR (Polymerase Chain Reaction) test and without symptoms
Exclusion
- any patient hypersensitive to hydroxychloroquine or under traditional herbal treatment in the two weeks preceding inclusion,
- any patient with other acute or chronic illnesses such as heart failure, arterial hypertension, renal failure, hepatocellular failure, tuberculosis or unable to take the oral treatment;
- any patient for whom one of the treatments under study is contraindicated according to the doctor's opinion.
- pregnant women,
- severe neurological manifestations
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
231 Patients enrolled
Trial Details
Trial ID
NCT04501965
Start Date
June 1 2020
End Date
September 30 2020
Last Update
August 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Support Centers of Donka, Kenien and Gbessia
Conakry, Guinea, 224